203 related articles for article (PubMed ID: 26797702)
1. Structural modeling of p.V31F variant in the aspartoacylase gene.
Krishnamoorthy N; Zayed H
Metab Brain Dis; 2016 Jun; 31(3):723-6. PubMed ID: 26797702
[TBL] [Abstract][Full Text] [Related]
2. Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme.
George Priya Doss C; Zayed H
Metab Brain Dis; 2017 Dec; 32(6):2105-2118. PubMed ID: 28879565
[TBL] [Abstract][Full Text] [Related]
3. Novel mutation in an Egyptian patient with infantile Canavan disease.
Zaki OK; El Abd HS; Mohamed SA; Zayed H
Metab Brain Dis; 2016 Jun; 31(3):573-7. PubMed ID: 26613958
[TBL] [Abstract][Full Text] [Related]
4. Two patients with Canavan disease and structural modeling of a novel mutation.
Zaki OK; Krishnamoorthy N; El Abd HS; Harche SA; Mattar RA; Al Disi RS; Nofal MY; El Bekay R; Ahmed KA; George Priya Doss C; Zayed H
Metab Brain Dis; 2017 Feb; 32(1):171-177. PubMed ID: 27531131
[TBL] [Abstract][Full Text] [Related]
5. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of aspartoacylase: implications for Canavan disease.
Hershfield JR; Pattabiraman N; Madhavarao CN; Namboodiri MA
Brain Res; 2007 May; 1148():1-14. PubMed ID: 17391648
[TBL] [Abstract][Full Text] [Related]
7. Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease.
Tacke U; Olbrich H; Sass JO; Fekete A; Horvath J; Ziyeh S; Kleijer WJ; Rolland MO; Fisher S; Payne S; Vargiami E; Zafeiriou DI; Omran H
Neuropediatrics; 2005 Aug; 36(4):252-5. PubMed ID: 16138249
[TBL] [Abstract][Full Text] [Related]
8. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
9. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Eke GH; Iscan A; Cece H; Calik M
Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
[TBL] [Abstract][Full Text] [Related]
10. Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.
Bitto E; Bingman CA; Wesenberg GE; McCoy JG; Phillips GN
Proc Natl Acad Sci U S A; 2007 Jan; 104(2):456-61. PubMed ID: 17194761
[TBL] [Abstract][Full Text] [Related]
11. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
[TBL] [Abstract][Full Text] [Related]
12. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
13. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
[TBL] [Abstract][Full Text] [Related]
14. Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.
Mendes MI; Smith DE; Pop A; Lennertz P; Fernandez Ojeda MR; Kanhai WA; van Dooren SJ; Anikster Y; Barić I; Boelen C; Campistol J; de Boer L; Kariminejad A; Kayserili H; Roubertie A; Verbruggen KT; Vianey-Saban C; Williams M; Salomons GS
Hum Mutat; 2017 May; 38(5):524-531. PubMed ID: 28101991
[TBL] [Abstract][Full Text] [Related]
15. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.
Kaul R; Gao GP; Balamurugan K; Matalon R
Nat Genet; 1993 Oct; 5(2):118-23. PubMed ID: 8252036
[TBL] [Abstract][Full Text] [Related]
16. Docking, molecular dynamics and free energy studies on aspartoacylase mutations involved in Canavan disease.
Kocak A; Yildiz M
J Mol Graph Model; 2017 Jun; 74():44-53. PubMed ID: 28349879
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease.
Zeng BJ; Wang ZH; Ribeiro LA; Leone P; De Gasperi R; Kim SJ; Raghavan S; Ong E; Pastores GM; Kolodny EH
J Inherit Metab Dis; 2002 Nov; 25(7):557-70. PubMed ID: 12638939
[TBL] [Abstract][Full Text] [Related]
18. Relationship between enzyme properties and disease progression in Canavan disease.
Zano S; Wijayasinghe YS; Malik R; Smith J; Viola RE
J Inherit Metab Dis; 2013 Jan; 36(1):1-6. PubMed ID: 22850825
[TBL] [Abstract][Full Text] [Related]
19. Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease.
Mersmann N; Tkachev D; Jelinek R; Röth PT; Möbius W; Ruhwedel T; Rühle S; Weber-Fahr W; Sartorius A; Klugmann M
PLoS One; 2011; 6(5):e20336. PubMed ID: 21625469
[TBL] [Abstract][Full Text] [Related]
20. Expression of aspartoacylase (ASPA) and Canavan disease.
Sommer A; Sass JO
Gene; 2012 Sep; 505(2):206-10. PubMed ID: 22750302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
